Trial Profile
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2022 Planned End Date changed from 1 Nov 2021 to 1 Jun 2023.
- 09 Jan 2022 Planned primary completion date changed from 1 Sep 2021 to 1 Jun 2022.
- 27 Jul 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Sep 2021.